Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
Travere Therapeutics, Inc. (RTRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.3% stake in Travere Therapeutics, Inc. |
| 10/04/2023 |
4
| Heerma Peter (Chief Commercial Officer) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 3,091 shares
@ $8.2511, valued at
$25.5k
|
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
8-K
| Quarterly results |
| 05/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/19/2023 |
4
| Baynes Roy D. (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Poole Sandra (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| COUGHLIN TIMOTHY (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Williams Brinkley Ruth (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Meckler Jeffrey A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Orwin John A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| LYONS GARY A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Bruhn Suzanne Louise (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/19/2023 |
4
| Squarer Ron (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 05/15/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in TRAVERE THERAPEUTICS, INC. |
| 05/12/2023 |
4
| Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 455 shares
@ $16.59, valued at
$7.5k
|
|
| 05/12/2023 |
4
| REED ELIZABETH E (SVP, GC & Corporate Secretary) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 825 shares
@ $16.59, valued at
$13.7k
|
|
| 05/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/13/2023 |
4
| Cline Christopher R. (CFO) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Sold 47 shares
@ $21.49, valued at
$1k
|
|
| 03/13/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.9% stake in Travere Therapeutics, Inc. |
| 03/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement, by and among Travere Therapeutics, Inc., Jefferies LLC, J.P. Morgan Securities LLC, BofA Securities, Inc. and SVB Securities LLC",
"Form of Pre-Funded Warrant",
"Opinion of Cooley LLP",
"Travere Therapeutics Announces Proposed Public Offering of Common Stock",
"Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants" |
|
| 03/01/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/27/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 6.2% stake in TRAVERE THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| MACQUARIE GROUP LTD reports a 5.5% stake in Travere Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 10% stake in TRAVERE THERAPEUTICS, INC. |
|
|
|